Issue of Options
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Issue of Options and Related Party Transaction
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that, the Company has issued 6,099,135 options over new ordinary shares with an exercise price of 16 pence per share ("New Options") to Stephen O'Hara, CEO of the Company. The New Options expire on 17 December 2034 and vest on the first anniversary of the options being granted being 17 December 2025.
The issue of the New Options follows the expiration of 6,099,135 options over new ordinary shares with an exercise price of 8 pence per share, granted to Stephen O'Hara, which expired in September 2024.
Related Party Transaction
The issuance of the New Options to Stephen O'Hara ("Transaction") is a related party transaction pursuant to Rule 13 of the AIM Rules.
The directors of the Company independent of the Transaction, having consulted with the Company's nominated adviser, Cairn Financial Advisers LLP, consider the terms of the Transaction to be fair and reasonable insofar as the Company's shareholders are concerned.
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Neil Davidson, Chairman | Contact via Walbrook below | |
Stephen O'Hara, Chief Executive | ||
|
| |
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner / Ludovico Lazzaretti | ||
| ||
Peterhouse Capital Limited (Joint Broker) | Tel: 020 7220 9797 | |
Duncan Vasey/ Lucy Williams
| ||
Walbrook PR Ltd | Mob: 07876 741 001 | |
Anna Dunphy | ||
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Stephen O'Hara | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial Notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | OptiBiotix Health Plc | |||||
b. | LEI | 213800UKYQFT941QHS14 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of 2p each
ISIN: GB00BP0RTP38 | |||||
b. | Nature of the transaction | Issue of options pursuant to the New Options
| |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
16p | 6,099,135 | ||||||
d. | Aggregated information - Volume - Price |
| |||||
e. | Date of the transaction | 17 December 2024 | |||||
f. | Place of the transaction | London | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.